$オンターナル セラピューティクス(ONCT.US)$Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of Onct-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
$オンターナル セラピューティクス(ONCT.US)$Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer 5 MINUTES AGO, 9:00 AM EDT VIA GLOBENEWSWIRE
Dr. Smith's advisory role will help shape the clinical strategy for ONCT-534. Her expectation is that the drug could deal with escape mechanisms of a specific prostate cancer, boosting its prospective efficiency and market validity.
Jesus is lordスレ主Den the Dragon:
I won't lie I have never had good experiences with this stock I am investing only tiny bitty position so that I can avg down conveniently without crying and if it goes up profit is profit
オンターナル セラピューティクスに関するコメント
5 MINUTES AGO, 9:00 AM EDT
VIA GLOBENEWSWIRE
@OBIfromMEM
まだコメントはありません